Modern Chinese Medicine issues profit warning, projecting at least RMB13.00 million loss for FY2025

Bulletin Express03-25

The Board of Modern Chinese Medicine Group Co., Ltd. announced a profit warning, indicating an expected net loss of no less than RMB13.00 million for the financial year ended 31 December 2025. This contrasts with the net profit of approximately RMB9.70 million recorded in FY2024.

The reversal from profit to loss is primarily attributed to four factors: 1. Loss of certain distributors, which directly affected sales channels. 2. Removal of best-selling products, including Cardiotonic Enhancement Capsule, from the national medical insurance list amid ongoing healthcare reforms, leading to lower demand. 3. Reduced purchase orders that kept unit fixed costs elevated. 4. Margin pressure from price reductions on other products that remain within the medical insurance catalogue.

The figures are based on the Group’s unaudited management accounts and may be adjusted upon completion of the annual audit. Modern Chinese Medicine expects to publish its full FY2025 results by the end of March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181235876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181235876","market":"us","top_or_hot":-1,"title":"Modern Chinese Medicine issues profit warning, projecting at least RMB13.00 million loss for FY2025","media":"Bulletin Express","content":"<p>The Board of Modern Chinese Medicine Group Co., Ltd. announced a profit warning, indicating an expected net loss of no less than RMB13.00 million for the financial year ended 31 December 2025. This contrasts with the net profit of approximately RMB9.70 million recorded in FY2024.</p>\n<p>The reversal from profit to loss is primarily attributed to four factors:\n1. Loss of certain distributors, which directly affected sales channels.  \n2. Removal of best-selling products, including Cardiotonic Enhancement Capsule, from the national medical insurance list amid ongoing healthcare reforms, leading to lower demand.  \n3. Reduced purchase orders that kept unit fixed costs elevated.  \n4. Margin pressure from price reductions on other products that remain within the medical insurance catalogue.</p>\n<p>The figures are based on the Group’s unaudited management accounts and may be adjusted upon completion of the annual audit. Modern Chinese Medicine expects to publish its full FY2025 results by the end of March 2026.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Modern Chinese Medicine issues profit warning, projecting at least RMB13.00 million loss for FY2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModern Chinese Medicine issues profit warning, projecting at least RMB13.00 million loss for FY2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-25 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Board of Modern Chinese Medicine Group Co., Ltd. announced a profit warning, indicating an expected net loss of no less than RMB13.00 million for the financial year ended 31 December 2025. This contrasts with the net profit of approximately RMB9.70 million recorded in FY2024.</p>\n<p>The reversal from profit to loss is primarily attributed to four factors:\n1. Loss of certain distributors, which directly affected sales channels.  \n2. Removal of best-selling products, including Cardiotonic Enhancement Capsule, from the national medical insurance list amid ongoing healthcare reforms, leading to lower demand.  \n3. Reduced purchase orders that kept unit fixed costs elevated.  \n4. Margin pressure from price reductions on other products that remain within the medical insurance catalogue.</p>\n<p>The figures are based on the Group’s unaudited management accounts and may be adjusted upon completion of the annual audit. Modern Chinese Medicine expects to publish its full FY2025 results by the end of March 2026.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01643","symbol_name":"现代中药集团","start_time":0,"source_url":"","article_id":"1181235876","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181235876","pubTimestamp":1774428166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The Board of Modern Chinese Medicine Group Co., Ltd. announced a profit warning, indicating an expected net loss of no less than RMB13.00 million for the financial year ended 31 December 2025. This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01643":"现代中药集团"},"translate_title":"现代中药发布盈利预警，预计2025财年亏损至少人民币1,300万元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01643":1},"content_text":"The Board of Modern Chinese Medicine Group Co., Ltd. announced a profit warning, indicating an expected net loss of no less than RMB13.00 million for the financial year ended 31 December 2025. This contrasts with the net profit of approximately RMB9.70 million recorded in FY2024.\nThe reversal from profit to loss is primarily attributed to four factors:\n1. Loss of certain distributors, which directly affected sales channels.  \n2. Removal of best-selling products, including Cardiotonic Enhancement Capsule, from the national medical insurance list amid ongoing healthcare reforms, leading to lower demand.  \n3. Reduced purchase orders that kept unit fixed costs elevated.  \n4. Margin pressure from price reductions on other products that remain within the medical insurance catalogue.\nThe figures are based on the Group’s unaudited management accounts and may be adjusted upon completion of the annual audit. Modern Chinese Medicine expects to publish its full FY2025 results by the end of March 2026.\nShareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181235876","isCrawlerRequest":true}